[1] |
RYŠKA A. Molecular pathology in real time[J]. Cancer Metastasis Rev, 2016, 35(1):129-140.
|
[2] |
CHEUNG W K, NGUYEN D X. Lineage factors and differentiation states in lung cancer progression[J]. Oncogene, 2015, 34(47):5771-5780.
DOI
PMID
|
[3] |
WANG D C, WANG X. Tomorrow's genome medicine in lung cancer[J]. Semin Cancer Biol, 2017, 42:39-43.
DOI
PMID
|
[4] |
DE SOUSA V M L, CARVALHO L. Heterogeneity in lung cancer[J]. Pathobiology, 2018, 85(1-2):96-107.
DOI
PMID
|
[5] |
ZITO MARINO F, BIANCO R, ACCARDO M, et al. Molecular heterogeneity in lung cancer:from mechanisms of origin to clinical implications[J]. Int J Med Sci, 2019, 16(7):981-989.
|
[6] |
杨安妮, 黎泳娥, 洪荣臻. DCE-MRI联合CA125、CA153对肺部良恶性肿块/结节鉴别效能及意义[J]. 中国CT和MRI杂志, 2022, 20(5):57-60.
|
[7] |
BALACHANDRAN V P, GONEN M, SMITH J J, et al. Nomograms in oncology:more than meets the eye[J]. Lancet Oncol, 2015, 16(4):e173-e180.
|
[8] |
ZWEIG M H, CAMPBELL G. Receiver-operating characteristic(ROC)plots:a fundamental evaluation tool in clinical medicine[J]. Clin Chem, 1993, 39(4):561-577.
|
[9] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
[10] |
CHEN F, LI J, QI X, et al. Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease[J]. J Cancer Res Ther, 2018, 14(Suppl):S400-S404.
|
[11] |
WU H, WANG Q, LIU Q, et al. The serum tumor markers in combination for clinical diagnosis of lung cancer[J]. Clin Lab, 2020, 66(3).
|
[12] |
张海晨, 王浩, 宋云霄, 等. 多项肿瘤标志物联合检测模型在肺癌诊断中的应用价值[J]. 检验医学, 2018, 33(7):590-596.
DOI
|
[13] |
张丽英, 傅冠华, 吴俊琪. 4项血清肿瘤标志物在肺癌辅助诊断和疗效评估中的价值[J]. 检验医学, 2019, 34(4):331-334.
DOI
|
[14] |
LI Y, CAO H, JIAO Z, et al. Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers[J]. Cancer Res, 2010, 70(20):8159-8168.
DOI
PMID
|
[15] |
ZHANG Z H, HAN Y W, LIANG H, et al. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer[J]. Cancer Med, 2015, 4(11):1633-1638.
|
[16] |
TAKADA M, MASUDA N, MATSUURA E, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay[J]. Br J Cancer, 1995, 71(1):160-165.
|
[17] |
GARCIA-VALDECASAS GAYO S, RUIZ-ALVAREZ M J, GONZALEZ-GAY D, et al. CYFRA 21-1 in patients with suspected cancer:evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value[J]. Adv Lab Med, 2020, 1(4):20200005.
|
[18] |
GENET S A A M, VISSER E, VAN DEN BORNE B E E M, et al. Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer[J]. Oncotarget, 2020, 11(27):2660-2668.
DOI
PMID
|
[19] |
MOLINA R, MARRADES R M, AUGÉ J M, et al. Assessment of a combined panel of six serum tumor markers for lung cancer[J]. Am J Respir Crit Care Med, 2016, 193(4):427-437.
|